Several reports have suggested that serum estimations of a number of tumour markers may be useful in assessing patients with cervical cancer. Carcinoma antigen 125 (CA125), squamous cell carcinoma antigen (SCC) and tissue polypeptide antigen (TPA) have all been identified, in elevated levels, in association with cervical carcinoma (Kato and Torigoe, 1977; Duk et al., 1989; Avall-Lundqvist et al., 1989 , 1992 . Pretreatment serum concentrations reflect stage of disease (Avall-Lundqvist et al., 1992) and have been shown to have prognostic significance (Maiman et al., 1989; Duk et al., 1990; Avall-Lundqvist et al., 1992; Ngan et al., 1994) .
In published studies evaluating the predictive potential of serum marker levels in carcinoma of the cervix, treatment has been variously by surgery, radiotherapy and chemotherapy, given either alone or in combination. Therefore, the present work was set up in order to investigate further the prognostic significance of the three serum tumour markers in carcinoma of the cervix treated more consistently, predominantly by radiotherapy alone. In addition, as few studies have evaluated the independence of predicting disease outcome after allowing for stage of disease (Avall-Lundqvist et al., 1992) , multivariate analyses were carried out to determine the independence of serum marker prognosis.
Materials and methods

Patients
Peripheral blood samples were obtained from patients who had been referred to the Christie Hospital for treatment for invasive primary carcinoma of the uterine cervix between June 1990 and September 1993. Informed consent was obtained from all patients. During examination under anaesthetic, a biopsy of the tumour was taken for independent assessment of diagnosis and histological grading. Clinical staging, according to the FIGO classification, of the patients was performed during the examination. All the patients were treated according to strict protocols. Only patients receiving radical treatment (i.e. with curative intent) were included in the analyses with patient outcome. The majority of these received radiotherapy alone as described previously . A small number were treated with curative intent with radiotherapy plus surgery (4) or chemotherapy (11). Twenty patients received palliative radiotherapy only and treatment follow-up was not obtained for 20 patients.
Serum marker analysis Peripheral blood samples were taken from the patients on the day before treatment with radiotherapy. These were separated as described elsewhere (Elyan et al., 1993) , coded and the serum stored at -80°C. All analyses were performed blind. The assays were carried out using commercially available kits. CA125 radioimmunoassay kits were purchased from CIS (UK) (High Wycombe, UK). SCC concentrations were estimated using the Abbott SCC RIABEAD (Abbott Laboratories, Chicago, II, USA) and TPA concentrations using PROLIFIGEN TPA IRMA (AB Sangtec Medical, Bromma, Sweden). The manufacturer's recommended procedures were followed throughout. Weak, but significant, correlations were seen between the levels of the different serum markers. There were, however, no significant associations between marker levels and either patient age, disease grade or tumour volume. The levels of SCC were significantly higher in 120 squamous cells tumours (11.8 ± 20.8 ng ml-1) compared with ten adenocarcinomas (0.7 ± 1.0 ng ml-'). No differences between tumour types were seen for either CA125 or TPA. For all serum markers, levels increased with increasing disease stage (Tables I-III) .
A comparison was made between the pretreatment serum marker levels found in patients who were either alive and well, or dead of disease following radiotherapy (1 year minimum follow-up time). Marker levels were significantly higher in the dead outcome group for all three markers studies (Table IV) . A comparison was also made between the pretreatment serum marker levels found in patients in relation to the development of metastatic disease. Patients who developed metastatic disease had significantly higher pretreatment serum marker levels (Table V) .
Using log-rank analysis and stratifying according to median values (the most objective criteria to use), a study was made of treatment outcome in terms of either survival (Figure 1 ), local control (Figure 2 ) or metastasis-free survival (Figure 3 ). For comparison, the prognostic ability of disease stage is illustrated for the same series of patients. Survival levels were significantly higher for patients with low (below the median) serum marker levels for all three markers studied. Serum marker levels were poorer at predicting local control levels compared with metastasis-free survival. A significant difference in local control was only seen for CA125 (Figure 2 ). However, significant differences in metastasis-free survival were seen for all tumour markers (Figure 3 ). For comparative purposes the data were also analysed using the manufacturer's recommended cut-off levels i.e. 2.5 ng ml' for SCC, 35 U ml-' for CA125 and 100 U ml-' for TPA. These cut-off levels are commonly used in the literature. Although the higher cut-off gave slightly better discrimination, similar results were obtained when the data were stratified by the two different methods (Table VI ).
An investigation was made of the independence of the (Table VII) . Using Cox multivariate analysis disease stage was the most important prognostic variable. After allowing for stage, only CA125 was a significant independent predictor of treatment outcome. Similar results were obtained when the data were analysed using two different cut-off levels.
Discussion
The serum marker levels found in this study were similar to those reported elsewhere. For example in 142 patients with carcinoma of the uterine cervix. Avall-Lundqvist et al. (1992) reported median values of 21 Uml-', 2ngml-' and 50 U ml-' for CA125, SCC and TPA respectively. Increasing marker levels with disease stage has also been described by others (e.g. Brioschi et al., 1991; Avall-Lundqvist et al., 1992) .
Using the manufacturer's recommended cut-off levels of 2.5 ngml-' for SCC, 35Uml-' for CA125 and 100 Uml-' for TPA, elevated levels were seen in 51%, 22% and 37% of patients for SCC, CA125 and TPA respectively (Tables  I-III) . These values are within the ranges reported by others using the same cut-off levels e.g. 44-57% for SCC (Duk et al., 1990; Avall-Lundqvist et al., 1992) , 23% for CA125 (Gadducci et al., 1990; Avall-Lundqvist et al., 1992) and 28-47% for TPA (Avall-Lundqvist et al., 1992; Ngan et al., 1994) .
Mean serum concentrations of SCC were 7 and 23 ng ml-' for patients free and dead of disease respectively. These values are similar to values reported elsewhere of 6 ng ml-' for patients with no evidence of disease and 16 ng ml ' for those with recurrent disease (Maiman et al., 1989) . This study has also confirmed that pretreatment measurements of the three markers can predict treatment outcome in carcinoma of the cervix. This has been reported for CA125 (Duk et al., 1990; Avall-Lundqvist et al., 1992) , SCC (Maiman et al., 1989; Duk et al., 1990; Ngan et al., 1994) and TPA (Ngan et al., 1994) . The larger analysis described here, however, is the first to show that CA125 is better at predicting recurrence-free survival whereas SCC and TPA predict for metastasis-free survival. In addition, studies published previously on cervical carcinoma involved treatment predominantly with surgery plus radiotherapy. Therefore, by confirming the prognostic significance of serum marker measurements for patients treated with radiotherapy alone, this study illustrates the independence of the findings from mode of treatment.
As reported here and elsewhere serum marker concentrations show a strong stage dependence. It is, therefore, not surprising to find that after allowing for stage the prognostic significance of all three markers was either lost or reduced. Only CA125 was shown to be an independent indicator of prognosis. This finding contrasts with the results of AvallLundqvist et al. (1992) who showed that both CA125 and SCC were significantly related to survival, in addition to stage. Similar levels of adenocarcinomas and squamous cell carcinomas, and similar follow-up times were found in both studies. Therefore, the disparate findings may be related to either differences in treatment methods, i.e. radiotherapy alone (this study) or predominantly surgery plus radiotherapy (Avall-Lundqvist et al., 1992) or differences in the (Avall-Lundqvist et al., 1992) .
Previous work by us has shown that measurements of tumour intrinsic radiosensitivity (assessed as surviving fraction at 2 Gy, SF2) are a good predictor of local control for carcinoma of the cervix treated with radiotherapy . It will be of interest in the future to combine the radiosensitivity data with that for the serum markers in particular to investigate whether SF2 and CA125 might combine to give a better prediction of locoregional failure than either alone. There is some preliminary evidence to suggest that SF2 and the serum markers are independent parameters. For 53 of the tumours studied in this work, SF2 values were obtained. There were no correlations between SF2 values and any of the marker levels (P> 0.20 for all). Tumour radiosensitivity data are still being accrued and a multivariate analysis will be carried out in the future.
In summary, this work has confirmed the prognostic significance of pretreatment measurements of serum markers in patients with cancer of the cervix. However, the study has shown that, after allowing for stage, their influence on treatment outcome is either lost or reduced and only CA125 appears to have any value as a pretreatment prognostic variable. In the future it will be of interest to evaluate CA125 alongside measurements of tumour intrinsic radiosensitivity. This will determine whether combinations of SF2 and CA 125 can improve the prediction of treatment outcome already reported for SF2 alone in carcinoma of the cervix undergoing radiotherapy.
